OverviewSuggest Edit

Elanco is a company that develops, manufactures, and markets products for animal health. It provides products and knowledge services to improve animal health and food-animal production. The company offers companion animal disease prevention products, such as parasiticide products, companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications, vaccines, nutritional enzymes, and animal-only antibiotics. It also delivers a range of food animal products used in ruminant and swine production.
TypePublic
Founded1954
HQGreenfield, IN, US
Websiteelanco.com
Employee Ratings3.8
Overall CultureF

Latest Updates

Employees (est.) (Dec 2019)6,080(+6%)
Job Openings410
Revenue (FY, 2020)$3.3 B(+7%)
Share Price (Sept 2021)$31.8
Cybersecurity ratingCMore

Key People/Management at Elanco

Jeff Simmons

Jeff Simmons

President and CEO of Elanco Animal Health
Ramiro M. Cabral

Ramiro M. Cabral

Executive Vice President, Elanco International
Julie Lawless

Julie Lawless

Senior Vice President, Corporate Affairs and Administration
Aaron Schacht

Aaron Schacht

Executive Vice President, Innovation, Regulatory and Business Development
Jacques Zimmowitch

Jacques Zimmowitch

Senior Vice President, Global Quality
Fadi Debes

Fadi Debes

Senior Vice President, Corporate Controller and Global Business Services
Show more

Elanco Office Locations

Elanco has offices in Greenfield, Manuel Alberti, Macquarie Park, Wien and in 34 other locations
Greenfield, IN, US (HQ)
2500 Innovation Way
Manuel Alberti, AR
Colectora Este Ramal Pilar
Macquarie Park, AU
Level 1/3-7 Eden Park Dr
Wien, AT
Gertrude-Fröhlich-Sandner-Straße 3
Antwerpen, BE
Plantin en Moretuslei 1a
Santo Antonio, BR
Condominio Parque da Cidade Avenida das Nacoes Unidas 13th Floor 14401 Chacara
Show all (39)

Elanco Financials and Metrics

Elanco Revenue

Embed Graph
View revenue for all periods
Elanco's revenue was reported to be $3.27 b in FY, 2020
USD

Revenue (FY, 2020)

3.3b

Gross profit (FY, 2020)

1.6b

Gross profit margin (FY, 2020), %

49.1%

Net income (FY, 2020)

(560.1m)

Market capitalization (22-Sept-2021)

15.0b

Closing stock price (22-Sept-2021)

31.8

Cash (31-Dec-2020)

494.7m

EV

20.7b
Elanco's current market capitalization is $15 b.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

2.9b3.1b3.1b3.3b

Revenue growth, %

6%0%

Cost of goods sold

1.5b1.6b1.5b1.7b

Gross profit

1.4b1.5b1.6b1.6b
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

736.2m770.2m761.1m731.1m781.6m771.3m657.7m586.3m889.6m

Cost of goods sold

360.0m431.5m369.8m343.8m356.0m360.4m332.7m295.9m441.8m

Gross profit

376.2m338.7m391.3m387.3m425.6m410.9m325.0m290.4m447.8m

Gross profit Margin, %

51%44%51%53%54%53%49%50%50%
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

323.4m474.8m345.1m494.7m

Accounts Receivable

567.4m651.8m816.9m871.6m

Prepaid Expenses

136.1m113.9m87.4m256.3m

Inventories

1.1b1.0b1.1b1.6b
Quarterly
USDQ3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

300.0m272.1m385.1m309.2m1.2b1.4b659.9m

Accounts Receivable

606.1m684.1m757.2m758.3m676.8m543.9m762.3m

Prepaid Expenses

123.2m114.8m102.3m98.0m132.1m107.4m180.6m

Inventories

1.0b1.0b1.1b1.1b1.0b1.1b1.6b
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(310.7m)86.5m67.9m(560.1m)

Depreciation and Amortization

318.4m296.0m314.5m516.9m

Inventories

(39.0m)(20.1m)(33.1m)(94.7m)

Accounts Payable

(8.4m)116.1m(29.2m)369.3m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

72.7m9.9m70.1m31.5m67.4m77.4m(49.1m)(102.3m)(237.3m)

Depreciation and Amortization

74.3m149.6m222.3m83.1m152.4m231.1m81.5m162.4m294.7m

Cash From Operating Activities

47.0m183.9m347.8m5.6m58.2m97.8m4.3m163.6m51.9m

Purchases of PP&E

(31.7m)(56.5m)(74.3m)(28.0m)(51.8m)(86.0m)(12.6m)(16.2m)
USDFY, 2017

Financial Leverage

1.1 x
Show all financial metrics

Elanco Operating Metrics

FY, 2018FY, 2019

Brands

125125

Countries

9090

Manufacturing Sites

1212

Patents and Patent Applications

3 k3 k
Show all operating metrics

Elanco Acquisitions / Subsidiaries

Company NameDateDeal Size
Prevtec Microbia IncJuly 31, 2019$60.3 m
Aratana TherapeuticsJuly 18, 2019$238 m
Boehringer Ingelheim Vetmedica IncJanuary 03, 2017$882.1 m
Janssen Animal Health BVBAJuly 07, 2011
ChemGen Corporation
Dista Products Limited
Elanco Animal Health, Korea, Ltd.
Elanco Animal Health (Pty) Ltd.
Elanco Animal Health UK Limited (FKA: Novartis Animal Health UK Limited)
Elanco Animal Vaccines Limited (FKA: Novartis Animal Vaccines Limited)
Show more

Elanco Revenue Breakdown

Embed Graph

Elanco revenue breakdown by business segment: 36.2% from FA Ruminants & Swine, 24.3% from FA Future Protein & Health, 11.3% from CA Therapeutics, 25.7% from CA Disease Prevention and 2.6% from Other

Elanco Cybersecurity Score

Cybersecurity ratingPremium dataset

C

75/100

SecurityScorecard logo

Elanco Online and Social Media Presence

Embed Graph

Elanco Company Culture

  • Overall Culture

    F

    49/100

  • CEO Rating

    B

    70/100

  • Compensation

    F

    10/100

Learn more on Comparably

Elanco News and Updates

Elanco Partners with AgBiome for Research Development

Greenfield-based Elanco Animal Health Inc. (NYSE: ELAN) has partnered with AgBiome Inc. in North Carolina to develop nutritional health products for swine. Using AgBiome’s strain identification system, Elanco will have access to the company's collection of bacteria, viral and fungal strains.

Elanco Closes Acquisition of Kindred Biosciences

Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has closed the acquisition of Kindred Biosciences.

Elanco to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, September 14, 2021. Jeff Simmons, president and CEO, will participate in a virtual fireside chat at 3:30 p.m. ET.

Elanco to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

Elanco to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

Elanco Animal Health Among Today’s Trending Stocks

Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. Today, our deep-learning algorithms have identified Elanco Animal Health among others.

What’s Next For Elanco Stock After A Large 16% Fall Yesterday?

The stock price of Elanco, a pharmaceuticals company focused on medicines for pets and livestock, has seen a large 19% fall over the last five trading days, and much of this fall has come in yesterday’s trading session (Aug 9), following the company’s Q2 release. While the company reported upbeat...
Show more

Elanco Frequently Asked Questions

  • When was Elanco founded?

    Elanco was founded in 1954.

  • Who are Elanco key executives?

    Elanco's key executives are Jeff Simmons, Ramiro M. Cabral and Julie Lawless.

  • How many employees does Elanco have?

    Elanco has 6,080 employees.

  • What is Elanco revenue?

    Latest Elanco annual revenue is $3.3 b.

  • What is Elanco revenue per employee?

    Latest Elanco revenue per employee is $538.4 k.

  • Who are Elanco competitors?

    Competitors of Elanco include Bimeda, Merck Animal Health USA and HIPRA.

  • Where is Elanco headquarters?

    Elanco headquarters is located at 2500 Innovation Way, Greenfield.

  • Where are Elanco offices?

    Elanco has offices in Greenfield, Manuel Alberti, Macquarie Park, Wien and in 34 other locations.

  • How many offices does Elanco have?

    Elanco has 39 offices.